KBC Group NV Sells 145,682 Shares of IQVIA Holdings Inc. $IQV

KBC Group NV lowered its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 24.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 458,070 shares of the medical research company’s stock after selling 145,682 shares during the quarter. KBC Group NV owned about 0.27% of IQVIA worth $72,187,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in IQV. Brighton Jones LLC boosted its holdings in shares of IQVIA by 244.4% during the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after buying an additional 2,537 shares in the last quarter. Ballentine Partners LLC boosted its stake in IQVIA by 4.9% during the first quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company’s stock worth $260,000 after acquiring an additional 69 shares in the last quarter. Mutual of America Capital Management LLC boosted its position in shares of IQVIA by 7.5% during the 1st quarter. Mutual of America Capital Management LLC now owns 34,435 shares of the medical research company’s stock worth $6,071,000 after purchasing an additional 2,405 shares in the last quarter. New York State Common Retirement Fund grew its stake in shares of IQVIA by 1.9% in the 1st quarter. New York State Common Retirement Fund now owns 104,480 shares of the medical research company’s stock valued at $18,420,000 after buying an additional 1,958 shares during the period. Finally, CWM LLC raised its stake in IQVIA by 4.0% during the 1st quarter. CWM LLC now owns 12,039 shares of the medical research company’s stock worth $2,122,000 after buying an additional 460 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the transaction, the insider directly owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This represents a 12.86% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.60% of the stock is currently owned by insiders.

IQVIA Stock Performance

Shares of IQV opened at $218.58 on Wednesday. The stock has a 50 day moving average of $200.53 and a 200 day moving average of $177.42. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $225.00. The company has a market capitalization of $37.22 billion, a price-to-earnings ratio of 29.98, a PEG ratio of 2.38 and a beta of 1.34.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.98 by $0.02. The firm had revenue of $4.10 billion during the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The business’s revenue was up 5.2% compared to the same quarter last year. During the same period last year, the firm posted $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on IQV shares. Robert W. Baird set a $258.00 price objective on IQVIA and gave the company an “outperform” rating in a research note on Wednesday, October 29th. Hsbc Global Res raised shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 9th. Citigroup upped their price objective on shares of IQVIA from $200.00 to $230.00 and gave the stock a “neutral” rating in a report on Wednesday, October 29th. Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a research report on Wednesday, October 8th. Finally, Jefferies Financial Group upgraded IQVIA from a “hold” rating to a “buy” rating and lifted their price target for the company from $195.00 to $225.00 in a research note on Tuesday, September 9th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and an average price target of $239.94.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.